Personalized treatment of cancers

Personalized treatment of cancers

The use of AONYS®-API microemulsions will allow effective delivery of APIs targeting specific genes or proteins in tumors, resulting in tumor growth inhibition and shrinkage. Once the therapeutic potential of the Aonys®-API combination has been validated in the mouse...
Pipeline

Pipeline

Products developed under classical NDA or 505/b(2) pathways   Research Preclinical Phase 1 Phase 2 NDA Filed NP03 Alzheimer  •••••••••••   •••••••••••   •••••••••••>     NP03 Huntington   •••••••••••   •••••••••••   •••••••••••>     NP01 Type 2 Diabetes...
Huntington’s disease

Huntington’s disease

HUNTINGTON’S DISEASE, HD Huntington’s Disease (HD) is a fatal autosomal dominant progressive neurodegenerative disease, characterized by progressive motor impairment (involuntary movements, chorea, dyskinesia, dystonia), psychiatric disturbances (change in mood,...
Drug to treat type 2 diabetes

Drug to treat type 2 diabetes

NP01 as treatment of metabolic anomalies linked to insulin resistance The incidence of diabetes is evolving rapidly favored by the growing obesity of populations all over the world. NP01 is an AONYS® microemulsion in which the active agent is a vanadium salt...